Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers say the biomarker could help noninvasively diagnose precancerous lung growths and distinguish them from benign nodules.
Checkpoint inhibitor immunotherapy, alone or in combination with chemotherapy, shows promise for advanced non-small-cell lung cancer.
Tecentriq plus chemotherapy and Avastin delays disease progression and death.
Cancer today feels like AIDS in the mid-1990s.
In non-small cell lung cancer, new drugs like brigatinib and crizotinib can dramatically shrink tumors with an ALK alteration.
Lorlatinib shrinks tumors in half of patients previously treated with older ALK inhibitors.
Immunotherapy combination reduced the risk of death by 36 percent compared with chemotherapy alone.
Median overall survival was 15.9 for the combination versus 11.3 months for chemotherapy alone.
Treatment with Opdivo appears to work well for HIV-positive people in small study.
Immunotherapy led to better outcomes for patients with inoperable non-small-cell lung cancer.
Targeted therapy approved first-line treatment of cancer with specific genetic mutations.
Targeted therapy reduced risk of disease progression or death by about 50 percent.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.